PL2846770T3 - Dooponowe podawanie inhibitorów mtor w terapii chorób neurodegeneracyjnych, chorób zapalnych układu nerwowego oraz chorób neuroonkologicznych - Google Patents

Dooponowe podawanie inhibitorów mtor w terapii chorób neurodegeneracyjnych, chorób zapalnych układu nerwowego oraz chorób neuroonkologicznych

Info

Publication number
PL2846770T3
PL2846770T3 PL13730352T PL13730352T PL2846770T3 PL 2846770 T3 PL2846770 T3 PL 2846770T3 PL 13730352 T PL13730352 T PL 13730352T PL 13730352 T PL13730352 T PL 13730352T PL 2846770 T3 PL2846770 T3 PL 2846770T3
Authority
PL
Poland
Prior art keywords
neurooncologic
neuroinflammatory
neurodegenerative
therapy
diseases
Prior art date
Application number
PL13730352T
Other languages
English (en)
Inventor
Tommaso CASSANO
Stefano GIOVAGNOLI
Alessandro MAGINI
Carla EMILIANI
Original Assignee
Dolcetta, Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dolcetta, Diego filed Critical Dolcetta, Diego
Publication of PL2846770T3 publication Critical patent/PL2846770T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13730352T 2012-05-11 2013-05-10 Dooponowe podawanie inhibitorów mtor w terapii chorób neurodegeneracyjnych, chorób zapalnych układu nerwowego oraz chorób neuroonkologicznych PL2846770T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000814A ITMI20120814A1 (it) 2012-05-11 2012-05-11 Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
EP13730352.5A EP2846770B1 (en) 2012-05-11 2013-05-10 Intrathecal administration of mtor inhibitors for the therapy of neurodegenerative, neuroinflammatory and neurooncologic diseases
PCT/IB2013/053792 WO2013168131A1 (en) 2012-05-11 2013-05-10 Intrathecal administration of mtor inhibitors for the therapy of neurodegenerative, neuroinflammatory and neurooncologic diseases

Publications (1)

Publication Number Publication Date
PL2846770T3 true PL2846770T3 (pl) 2019-02-28

Family

ID=46582908

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13730352T PL2846770T3 (pl) 2012-05-11 2013-05-10 Dooponowe podawanie inhibitorów mtor w terapii chorób neurodegeneracyjnych, chorób zapalnych układu nerwowego oraz chorób neuroonkologicznych

Country Status (10)

Country Link
US (2) US20150132397A1 (pl)
EP (1) EP2846770B1 (pl)
CN (1) CN104427975A (pl)
DK (1) DK2846770T3 (pl)
ES (1) ES2686561T3 (pl)
IN (1) IN2014MN02475A (pl)
IT (1) ITMI20120814A1 (pl)
PL (1) PL2846770T3 (pl)
PT (1) PT2846770T (pl)
WO (1) WO2013168131A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
GB2564383B (en) * 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
CN109187839A (zh) * 2018-10-25 2019-01-11 美康生物科技股份有限公司 准确测定人全血中四种免疫抑制剂类药物浓度的试剂盒及检测方法
CN109406650A (zh) * 2018-10-25 2019-03-01 美康生物科技股份有限公司 用于准确测定人全血中四种免疫抑制剂类药物浓度的试剂盒及检测方法
IT202000007228A1 (it) 2020-04-06 2021-10-06 Diego Dolcetta SOMMINISTRAZIONE DI INIBITORI DI mTOR NEL SISTEMA NERVOSO CENTRALE
CN116348769A (zh) * 2020-07-14 2023-06-27 詹森药业有限公司 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
CA3199806A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
IT202300006672A1 (it) * 2023-04-05 2024-10-05 Alberto Chiarugi Trattamento delle encefalomielopatie progressive
CN119745904A (zh) * 2024-11-27 2025-04-04 澳门大学 芍药苷在制备治疗结节性硬化症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2499599A1 (en) * 2002-09-17 2004-04-01 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
US20080207671A1 (en) * 2006-07-31 2008-08-28 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20090274764A1 (en) * 2008-04-30 2009-11-05 Do Hiep Q Hollow Foam Beads for Treatment of Glioblastoma
EP2456437A4 (en) * 2009-07-24 2013-01-09 Inst Nat Rech Scient COMBINATIONS OF CURCUMOIDENE AND MTOR INHIBITORS FOR THE TREATMENT OF TAUOPATHIES

Also Published As

Publication number Publication date
US20160324770A1 (en) 2016-11-10
CN104427975A (zh) 2015-03-18
WO2013168131A1 (en) 2013-11-14
IN2014MN02475A (pl) 2015-07-10
ES2686561T3 (es) 2018-10-18
US20150132397A1 (en) 2015-05-14
DK2846770T3 (en) 2018-09-17
EP2846770B1 (en) 2018-06-13
EP2846770A1 (en) 2015-03-18
ITMI20120814A1 (it) 2013-11-12
PT2846770T (pt) 2018-10-15

Similar Documents

Publication Publication Date Title
IL269852B (en) Combined treatments and uses for the treatment of demyelination disorders
PT2846770T (pt) Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas
IL238575A0 (en) Systems and methods for administering drugs to the lung
EP3068353A4 (en) Systems and methods for subretinal delivery of therapeutic agents
PT2726141T (pt) Dispositivo para administração oral de compostos terapêuticos
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
EP3060173A4 (en) Methods and systems for heart valve therapy
EP2699199A4 (en) SYSTEMS AND METHODS FOR BARIATRIC THERAPY
IL237138A0 (en) Methods of administration of pirfenidone therapy
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
IL263661A (en) Combination therapy for the treatment of glioblastoma
EP3010486A4 (en) Chemical structures for localized delivery of therapeutic agents
EP2968739A4 (en) Infusion systems for the controlled delivery of therapeutic agents
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
IL246286B (en) A medical preparation for the prevention and treatment of advanced myopia.
ZA201504065B (en) Therapeutic agent for keratoconjunctive disorders
EP3075380A4 (en) Drug for treating vertebrae cervicales and lumber diseases
EP3046556A4 (en) Combination drug therapy
PT2922541T (pt) Piridil-hidrazonas para o tratamento de tuberculose e doenças relacionadas
EP3049075A4 (en) Laquinimod combination therapy for treatment of multiple sclerosis
AU2012902640A0 (en) Dosage Regime for Animal Treatment
HK1225291A1 (en) Laquinimod combination therapy for treatment of multiple sclerosis
PL2934528T3 (pl) Hydrazony chinolilowe do leczenia gruźlicy i chorób pokrewnych